Page 21 - JCTR-11-4

Journal of Clinical and
Translational Research Hidden cancer after VTE

developed using ML techniques hold promise for accurately References
identifying VTE patients at elevated risk for occult cancer.
1. Baron JA, Gridley G, Weiderpass E, Nyrén O,
A few limitations to our analysis should be acknowledged. Linet M. Venous thromboembolism and cancer. Lancet.
Differences were observed among the studies regarding 1998;351(9109):1077-1080.
patient characteristics, screening strategies, the time between doi: 10.1016/S0140-6736(97)10018-6
the episode of VTE and screening, and the follow-up period.
However, the conclusions are based on data collected from 2. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH,
Nielsen GL. The risk of a diagnosis of cancer after primary
more than 2,000 patients. The study also did not measure VTE‐ deep venous thrombosis or pulmonary embolism. N Engl J
related mortality, adverse effects of anticoagulation, adverse Med. 1998;338(17):1169-1173.
effects of cancer tests, participant satisfaction, or quality of life;
consequently, the impact of these factors remains unknown. doi: 10.1056/NEJM199804233381701
3. Lee AY, Levine MN. Venous thromboembolism
5. Conclusion and cancer: Risks and outcomes. Circulation. 2003;
107(23 Suppl 1):I17-I21.
This meta-analysis explores the usefulness of cancer
screening in patients with unprovoked VTE. RCT data doi: 10.1161/01.CIR.0000078466.72504.AC
demonstrated that thorough screening enables earlier 4. White RH, Chew HK, Zhou H, et al. Incidence of venous
detection of cancer in patients with unprovoked VTE. thromboembolism in the year before the diagnosis of cancer
However, this early detection does not improve overall in 528,693 adults. Arch Intern Med. 2005;165(15):1782-1787.
patient survival or decrease cancer-related mortality. doi: 10.1001/archinte.165.15.1782
Consequently, current guidelines do not recommend
extensive cancer screening for patients with unprovoked 5. Prandoni P, Lensing AW, Büller HR, et al. Deep-vein
VTE, leaving the decision to screen at the discretion of thrombosis and the incidence of subsequent symptomatic
cancer. N Engl J Med. 1992;327(16):1128-1133.
individual clinicians on a case-by-case basis.
doi: 10.1056/NEJM199210153271604
Acknowledgments 6. Hettiarachchi RJ, Lok J, Prins MH, Büller HR,

None. Prandoni P. Undiagnosed malignancy in patients with deep
vein thrombosis: Incidence, risk indicators, and diagnosis.
Funding Cancer. 1998;83(1):180-185.

None. doi: 10.1002/(sici)1097-0142(19980701)83:1<180:aid-
cncr24>3.0.co;2-s
Conflict of interest 7. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer
The authors declare that they have no competing interests. in patients with primary venous thromboembolism:
A national, population-based cohort study. Br J Cancer.
Author contributions 2004;91(1):92-95.
Conceptualization: Anabel Franco-Moreno doi: 10.1038/sj.bjc.6601964
Formal analysis: Anael Franco-Moreno, José Manuel Ruiz- 8. Schulman S, Lindmarker P. Incidence of cancer after
Giardín prophylaxis with warfarin against recurrent venous
Methodology: All authors thromboembolism. Duration of anticoagulation trial.
Writing–original draft: All authors N Engl J Med. 2000;342(26):1953-1958.
Writing–review & editing: All authors doi: 10.1056/NEJM200006293422604
Ethics approval and consent to participate 9. Sandén P, Svensson PJ, Själander A. Venous
thromboembolism and cancer risk. J Thromb Thrombolysis.
Not applicable. 2017;43(1):68-73.
doi: 10.1007/s11239-016-1411-y
Consent for publication
10. Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T,
Not aplicable. Rodger MA. Systematic review: The Trousseau syndrome
revisited: Should we screen extensively for cancer in
Availability of data patients with venous thromboembolism? Ann Intern Med.

The datasets generated and analyzed for the current study 2008;149:323-333.
are available from the corresponding author. doi: 10.7326/0003-4819-149-5-200809020-00007

Volume 11 Issue 4 (2025) 15 doi: 10.36922/jctr.24.00069